

AMENDMENTS TO THE CLAIMS

1 - 123. (Canceled).

124. (NEW) A crystalline form of azithromycin, wherein said form is substantially pure Form F.

125. (NEW) A pharmaceutical dosage form comprising said substantially pure Form F of claim 124.

126. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F is characterized as containing 2-5% water and 1-5% ethanol by weight in a powder sample.

127. (NEW) The pharmaceutical dosage form of claim 126, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum comprising at least one peak with chemical shift of about 179.5 ppm.

128. (NEW) The pharmaceutical dosage form of claim 127, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 178.6 ppm.

129. (NEW) The pharmaceutical dosage form of claim 128, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 58.0 ppm.

130 (NEW) The pharmaceutical dosage form of claim 129, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 17.2 ppm.

131. (NEW) The pharmaceutical dosage form of claim 130, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 10.1 ppm.

132. (NEW) The pharmaceutical dosage form of claim 131, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 9.8 ppm.
133. (NEW) The pharmaceutical dosage form of claim 132, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 9.3 ppm.
134. (NEW) The pharmaceutical dosage form of claim 133, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 7.9 ppm.
135. (NEW) The pharmaceutical dosage form of claim 134, wherein said substantially pure Form F is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 6.6 ppm.
136. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 82% or more by weight of form F azithromycin.
137. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 84% or more by weight of form F azithromycin.
138. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 86% or more by weight of form F azithromycin.
139. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 88% or more by weight of form F azithromycin.
140. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 90% or more by weight of form F azithromycin.
141. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 94% or more by weight of form F azithromycin.

142. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 98% or more by weight of form F azithromycin.
143. (NEW) The pharmaceutical dosage form of claim 125, wherein said substantially pure Form F comprises 99% or more by weight of form F azithromycin.